Equity · Healthcare
HURA
NASDAQTuHURA Biosciences, Inc./NV (HURA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 148.0M USD
- Revenue, year to Dec 2025
- 0 USD
- EPS, diluted, year to Dec 2025
- −0.63 USD
- 52-week range
- 0.4396 USD – 3.24 USD
- Avg volume
- 122.2K
as of Jul 17, 2026
Have TuHURA Biosciences, Inc./NV (HURA) insiders bought or sold shares recently?
In the 90 days to 20 Nov 2026, no TuHURA Biosciences, Inc./NV insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).
Form 4, 90 days to 20 Nov 2026, newest Form 4 filing 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Bianco James A.Chief Executive Officer | Gift | 75,000 |
Which funds hold TuHURA Biosciences, Inc./NV (HURA)?
3 of the 45 institutional funds we track reported a TuHURA Biosciences, Inc./NV position for the quarter ended 30 Sep 2026 — a combined 953K USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Trimmed | 281,328 | 591K USD | −38.1% |
| AQR Capital Management | Trimmed | 110,891 | 233K USD | −73.9% |
| Citadel Advisors | Trimmed | 61,717 | 130K USD | −73.4% |
| Tudor Investment Corp | Exited |
Have members of Congress traded TuHURA Biosciences, Inc./NV (HURA)?
The most recent congressional trade disclosed in TuHURA Biosciences, Inc./NV is a purchase by Laurel M. Lee (house, FL), dated 25 Nov 2024.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 25 Nov 2024 | Laurel M. Leehouse · Republican–FL | Purchase | 1K USD–15K USD | 43 days |
| 18 Oct 2024 | Laurel M. Leehouse · Republican–FL | Exchange | 100K USD–250K USD | 34 days |
What has been filed or recorded for TuHURA Biosciences, Inc./NV (HURA)?
The filings we hold for TuHURA Biosciences, Inc./NV, newest first: 14 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,668 shares | 8K USD notional · 0.006% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,725 shares | 5K USD notional · 0.004% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,019 shares | 2K USD notional · 0.002% of shares out |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 18,500 shares | 38K USD notional · 0.028% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,230 shares | 13K USD notional · 0.009% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,122 shares | 2K USD notional · 0.002% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,207 shares | 2K USD notional · 0.002% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,861 shares | 5K USD notional · 0.004% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,189 shares | 2K USD notional · 0.002% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,729 shares | 18K USD notional · 0.015% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 24,648 shares | 48K USD notional · 0.037% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 709 shares | 1K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,743 shares | 11K USD notional · 0.009% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,210 shares | 4K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.10 USD | |
| 30 Sep 2026 | Financials | Total assets | 36.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 19.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.14 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.13 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.63 USD | |
| 31 Dec 2025 | Financials | Revenue | 0 USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −30.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.63 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.14 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.21 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.15 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.21 USD |
What do people ask about TuHURA Biosciences, Inc./NV (HURA)?
What is TuHURA Biosciences, Inc./NV’s market cap?148.0M
TuHURA Biosciences, Inc./NV is worth 148.0M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is TuHURA Biosciences, Inc./NV’s revenue?0
TuHURA Biosciences, Inc./NV reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have TuHURA Biosciences, Inc./NV insiders bought or sold shares recently?1 filing
In the 90 days to 20 Nov 2026, no TuHURA Biosciences, Inc./NV insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4). See Insiders
Which funds own TuHURA Biosciences, Inc./NV?3 of 45
3 of the 45 funds we track reported a TuHURA Biosciences, Inc./NV position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, AQR Capital Management and Citadel Advisors. See Funds
Have members of Congress traded TuHURA Biosciences, Inc./NV?2 trades
Yes. 2 trades in TuHURA Biosciences, Inc./NV appear in the congressional disclosures we hold; the latest is a purchase by Laurel M. Lee (House, FL) dated 25 Nov 2024, filed 7 Jan 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did TuHURA Biosciences, Inc./NV last report earnings?−0.10
TuHURA Biosciences, Inc./NV last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.10 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Laurel M. Lee: Government of Florida, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words